Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data

Top-Line Data Expected in the Fourth Quarter of 2015 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. Shares of the 87-employee biotech in Alewife doubled yesterday after it said its potential blockbuster vaccine in development to prevent herpes .. http: //www. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements. Current genital herpes therapies only partially control clinical symptoms and viral shedding, a process which drives disease transmission. ET. Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies.

Astellas Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. Just this month over a third of respondents in a poll conducted by BioSpace (DHX) believe that AstraZeneca PLC could be in the running to acquire struggling GlaxoSmithKline (GSK). For more information, please visit the company’s website at It can be transmitted to sexual partners, even when the disease is asymptomatic. – Increase in CD4+ polyfunctional T cells indicates GEN-003 is stimulating a multi-faceted T cell immune response to genital herpes – – GEN-003 elicited strong antibody responses at 12 months post-dosing – CAMBRIDGE, Mass., Oct. GEN-003 is a first-in-class T cell-directed immunotherapy designed to elicit both a T cell and B cell (antibody) immune response. ATLAS screening has already identified novel T cell antigens, including those which appear to be associated with natural immunity against EBV infection and antigen selection and prioritization is ongoing.

Pritelivir is an innovative, highly active and specific inhibitor of herpes simplex virus (HSV). Further details about this trial can be found at, NCT02030301. (1) Muller WJ et al. In a time when medicine is reaching new heights – immunotherapies that are curing certain cancers, or more and more sophisticated transplantations are possible – it is unthinkable that antibiotic resistance could cause a future that mirrors the days before antibiotics were developed; where people had to die of common infections, and where many medical interventions that today we take for granted, like including general surgery, were highly risky if not impossible. Genital Herpes affects more than 400 million people worldwide and causes recurrent, painful genital lesions. Genocea plans to use these insights to help prospectively define, in a commercial or clinical setting, patients who could benefit from these therapies. The company expects the trial to enlist quickly, given the overwhelming interest in the program.

We note that Genocea has another T cell-enabled candidate in its pipeline, GEN-004, for the prevention of infections caused by pneumococcus. For that reason, only the most risk-tolerant investors should consider buying shares in this high-risk, high-reward company. Guest speaker Charles G. The latter of these – viral shedding – is considered one of the key metrics by Genocea in determining efficacy of GEN-003. HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. The primary endpoint of this trial is a composite of overall mortality and CMV end organ disease. Based on clinical data to date, as well as market research showing the significant dissatisfaction among patients with current treatment options for genital herpes, GEN-003 may offer patients an important new treatment option with the promise of improved ‘real-world’ clinical outcomes and sustained reductions in viral shedding with the convenience of annual maintenance dosing.

Specifically, a single course of treatment of GEN-003 may offer benefits similar to a full year of daily administration of oral antivirals – but with greatly improved convenience. The vaccine will be evaluated with Vical’s Vaxfectin® adjuvant. A seventh group received placebo. Coming back to the press release, data showed that GEN-003 demonstrated statistically significant improvements in comparison with placebo across multiple clinical endpoints at six months after dosing. Subjects were randomized in a 1:1 ratio to receive GEN-004 or placebo. “Anza” Mammen, M.D. As the company is billing both experimental products as having blockbuster potential, investors should definitely keep their eyes peeled for these upcoming clinical updates.

Genocea Biosciences Inc. Genocea is expected to announce top-line viral shedding data in mid-2016. Shares of the company gained approximately 4% on the news. The company plans to use the proceeds of the offering to support the clinical development of GEN-003 and GEN-004, which are both currently in phase 2 development as treatment options for genital herpes and pneumococcus, respectively. 14, 2016 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. Rübsamen-Schaeff was CEO of AiCuris since its foundation in 2006 as a spin out from the infectious disease unit of Bayer Healthcare, also previously led by her. Genocea essentially collapsed on the Tweet, and failed to recover throughout the remainder of the year.

Posters Background:  Genital HSV-2 infection is the most common cause of genital ulcers worldwide.